Indication

Kaposi's sarcoma

Kaposi's sarcoma is a low-grade vascular neoplastic disorder caused by infection with human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus. Read more about Kaposi's sarcoma

41 drugs 33 manufacturers

Advertisement

Drugs that treat it

Common Kaposi's sarcoma therapies.

Showing 10–18 of 41 drugs

PACLITAXEL

ANTINEOPLASTIC - TAXANES·KAPOSI'S SARCOMA·+5
MYLAN INSTITUTI

PACLITAXEL

ANTINEOPLASTIC - TAXANES·KAPOSI'S SARCOMA·+5
WG CRITICAL CAR

PACLITAXEL

ANTINEOPLASTIC - TAXANES·KAPOSI'S SARCOMA·+5
APP/FRESENIUS K
Filter & compare in the drug finder →Opens the drug finder with Kaposi's sarcoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Kaposi's sarcoma.

Kaposi's sarcoma is a low-grade vascular neoplastic disorder caused by infection with human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus.

It primarily affects individuals with compromised immune systems—notably people living with advanced HIV infection (AIDS-defining illness) and solid-organ transplant recipients—as well as distinct demographic groups presenting with classic (older Mediterranean or Eastern European men) or endemic (equatorial African) forms.

Pathophysiologically, the tumor arises from lymphatic endothelial-lineage cells, leading to multifocal vascular proliferation, spindle-cell infiltration, and extravasated erythrocytes.

Clinically, it manifests as nonpruritic, violaceous, brownish, or reddish macules, plaques, and nodules that commonly involve the skin, oral mucosa, and lymph nodes, with potential dissemination to the gastrointestinal and respiratory tracts causing mucosal bleeding or airway compromise.

Personalize your experience

Follow Kaposi's sarcoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it